Research

Department of Medicine
Rutgers New Jersey Medical School
Associate Professor
July 2015-Present

Department of Medicine
Rutgers New Jersey Medical School (formerly University of Medicine and Dentistry of New Jersey)
Assistant Professor
2/2004-June 2015

Department of Medicine
Mount Sinai School of Medicine, New York, NY
Clinical Educator
July 2000-June 2001

Medical Director
Infectious Diseases Practice
University Hospital, Newark, NJ
August 2014 to present

Associate Medical Director
Infectious Diseases Practice
University Hospital, Newark, NJ
2008 to August 2014

Medical Director
HIV-Hepatitis C Co-infection Clinic
University Hospital, Newark, NJ
2006-Present

Department of Medicine
Attending Physician
University Hospital, Newark, NJ
2/2004 to present

Department of Medicine
Staff Physician
Englewood Hospital and Medical Center
7/2001 to 5/2004

LICENSURE:
New Jersey Medical License MA 71860, Exp. 6/30/2021
New York Medical License 229288 (inactive)

CERTIFICATION:
Specialty Board: Internal Medicine Certified 2000 Recertified 2010
Subspecialty Board: Infectious Diseases Certified 2003; Recertified 2013

NARCOTICS CERTIFICATION:
New Jersey CDS DO8468400, Exp. 10/31/2018
DEA BS8516582, Exp. 2/28/2021

MEMBERSHIPS, OFFICES AND COMMITTEE ASSIGNMENTS IN PROFESSIONAL SOCIETIES:

Member, Infectious Diseases Society of America                      2003-Present

Member, HIV Medicine Association                                            2003-Present

SERVICE ON NATIONAL GRANT REVIEW PANELS, STUDY SECTIONS, COMMITTEES:

Member of the Executive Committee, AIDS Clinical Trials Group. January 2019- Current

Member of the New Jersey Governor’s End the Epidemic Task Force

Member of the Women’s Intersciences Health Committee, AIDS Clinical Trials Group, January 2017- 2018

Featured Expert: New England Journal of Medicine: Treatment of Hepatitis C Forum, June 2015

Member of the Underrepresented Populations Committee, AIDS Clinical Trials Group, January 2015- 2018

Continuous Education Academic Advisor, New Jersey AIDS Line, January 2014-Present

Beta-tester, Infectious Diseases Society of America, Maintenance of Certification Module, Hepatitis C Infection, May 2013.

Beta-tester, Infectious Diseases Society of America, Maintenance of Certification Module, Infections in the non-HIV immunocompromised host, April 2012

Member of the Hepatitis Committee, AIDS Clinical Trials Group, 2009-2011

HIV Care and Treatment Committee, Newark Emergency Metropolitan Agency
City of Newark, 2008-2012

SERVICE ON MAJOR COMMITTEES:
Medical School

Member, Human Studies Subcommittee, Institutional Review Board
Rutgers, New Jersey Medical School, 2013 to present

Member, Human Studies Subcommittee, Institutional Review Board
University of Medicine and Dentistry of New Jersey – New Jersey Medical School, Newark, NJ
2011-2013

Member, Hepatitis B Evaluation Committee
University of Medicine and Dentistry of New Jersey – New Jersey Medical School, Newark, NJ
2010-2013

Member, Rutgers Clinical Operations/ Ambulatory Logistics Workgroup
2020-Current

Hospital

Chair, HIV Management Committee, Infectious Diseases Practice
University Hospital, Newark, 2014-present

Chair, HIV Providers Committee, Infectious Diseases Practice
University Hospital, Newark, 2014-present

Chair, Multi-Disciplinary Committee, Infectious Diseases Practice
University Hospital, Newark, 2014-present

Chair, Ryan White Planning Committee, Infectious Diseases Practice
University Hospital, Newark, 2014-present

Chair, Continuous Quality Committee, Infectious Diseases Practice
University Hospital, Newark, 2014-Present

Chair, HIV Primary Medical Home, Infectious Diseases Practice
University Hospital, Newark, January 2013-December 2013

Member, EPIC Super User for Outpatient Infectious Diseases Practice
University Hospital, Newark, 2011-2012

Member, Ambulatory Care Committee

University Hospital, Newark, 2011-present

Member, HIV Management Committee, Infectious Diseases Practice
University Hospital, Newark, 2014-present

Member, Continuous Quality Committee, Infectious Diseases Practice
University Hospital, Newark, 2008-2014

Member, Antimicrobial Sub-Committee

University Hospital, Newark, 2008-present

Member, Multi-Disciplinary Committee, Infectious Diseases Practice
University Hospital, Newark, 2006-2014

Member, HIV Providers Committee, Infectious Diseases Practice
University Hospital, Newark, 2006-2014

Chair, HIV-Hepatitis C Committee, Infectious Diseases Practice

University Hospital, Newark, 2006-present

Member, Ryan White Planning Committee, Infectious Diseases Practice
University Hospital, Newark, 2006-2014

Chair, Hepatitis C Education Group Committee, Infectious Diseases Practice
University Hospital, Newark, 2006-present

Non-Voting Member, Consumer Advisory Board, Infectious Diseases Practice
University Hospital, Newark, 2005-2010

Member, Infection Control Committee

Englewood Hospital and Medical Center, 2000-2001

Member, Quality Improvement Committee

Englewood Hospital and Medical Center, 2000-2001

Member, Medical Education Committee

Englewood Hospital and Medical Center, 2000-2001

Department

Course Director, Infectious Diseases Journal Club Series

Department of Medicine, Rutgers New Jersey Medical School (formerly University of Medicine

and Dentistry of New Jersey), 2007 to 2013

Editorial Boards

None

Ad Hoc Reviewer

AIDS Line 2008 to January 2014

SERVICE TO THE COMMUNITY:

Montclair Special Education Parent Advisory Committee

Montclair, NJ 2006-present

Planning Committee 2011

Fragile X Association of New Jersey

Planning Committee 2009

Fragile X Association of New Jersey

A. Principle Investigator

• HVTN 706/VAC89220HPX3002 (MOSAICO). A study of heterologous vaccine regimen of Adenovirus Serotype 26 Mosaic4 Human Immunodeficiency Virus (AD26.Mos4.HIV), Adjuvanted Clade C gp140 and Mosaic gp140 to prevent HIV-1 infection among cis-gender men and transgender individuals who have sex with cisgender med and/or transgender individuals (Funded by Janssen therapeutics). July 2020
• HVTN 405/HPTN 190 Characterizing SARS-CoV-2-specific immunity in convalescent individuals (Funded by National Institutes of Health). May 2020-Current
• HVTN 406/HPTN 1902 CoVPN 5001 A prospective study of acute immune responses to SARS-CoV-2 infection. (Funded by National Institutes of Health) June 2020
• GS-US-540-5807 – COVID-19 Real World Cohort. (Funded by Gilead Sciences) March 2020-Current (Estimated 160,800)
• CINJ 002011:  Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19 (Funded by CINJ) April 2020-Current
• HPTN 083 A Phase 2b/3 Double Blind Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC), For Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender Women who have Sex with Men. December 1, 2016-November 30, 2017. (1, 185275)
• HPTN 085 A Phase 2B Study to Evaluate the Safety and Efficacy of VRC01 Broadly Neutralizing Monoclonal Antibody in Reducing Acquisition of HIV-1 Infection. December 1, 2015-November 30, 2016 ($659,371)
• Hepatitis C Virus Treatment Response to Ledipasvir/Sofosbuvir among persons Co-Infected with HIV and HCV: Real World Data in a Predominantly Black Population. Gilead Sciences March 3, 2016-February 28, 2017 ($79,445)
• Positive Health Check Evaluation Trial– Research Triangle International. Centers for Disease Control and Prevention (117,000) September 2015-Current
• Universal HIV Testing in the Emergency Department at University Hospital, Newark, NJ. Gilead Sciences (annual budget $300,000). January 2015-December 2017
• UM1 AI068619 HPTN 076: Phase II Safety and Acceptability of an Investigational Injectable Product, TMC278 LA, for Pre-Exposure Prophylaxis (PrEP) ($1,144,544) January 2015-December 2016 ($79,500 awarded)
• 2UM1AI069419 Weill Cornell Medical College-New Jersey Medical School AIDS Clinical Trials Unit (CTU); NIH-NIAID (Site PI) (December 2013-November 2014: $1,099,189); (December 1, 2014- November 30, 2015:$1,065,651); (December 2015- November 2016: $1,280,275) Funds Following Projects:
  • A5320: Viral Hepatitis C Infection Long-term Cohort Study (V-HICS) (Funded under the NIH-NIAID CTU) November 2016-Current
  • A5324: A Randomized, Double-Blinded, Placebo-Controlled Trial Comparing Antiretroviral Intensification with Maraviroc and Dolutegravir with No Intensification or Intensification with Dolutegravir Alone for the Treatment of Cognitive Impairment in HIV
  • A5329: Interferon-Free Therapy for Chronic Hepatitis C Virus Genotype 1 Infection in Participants with HIV-1 Coinfection Receiving Concurrent Antiretroviral Therapy
    (C_ASCENT)
  • A5337: Safety and Efficacy of Sirolimus for HIV Reservoir Reduction in Individuals on Suppressive Antiretroviral Therapy
  • A5349: Rifapentine-containing treatment shortening regimens for pulmonary tuberculosis:
    A randomized, open label, controlled phase 3 clinical trial
  • A5350: Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
  • A5352s: Effects of the Probiotic Visbiome Extra Strength on Epithelial Barrier Function and Inflammation in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Sub study of A5350
  • A5332: Randomized Trial to Prevent Vascular Events in HIV – REPRIEVE (A5332)
  • A5333s: Effects of Pitavastatin on Coronary Artery Disease and Inflammatory Biomarkers: Mechanistic Sub study of REPRIEVE
  • WOW: Womens’ Outreach Worker to increase enrolment of women in ACTG studies
  • A5325: A Prospective Randomized Controlled Study to Evaluate the Effect of Isotretinoin on Immune Activation Among HIV-1 Infected Subjects with Incomplete CD4+ T Cell Recovery on Suppressive ART (Funded under the NIH-NIAID CTU) January 2015-Current
  • A5330s: Evaluation of CD4+ T Cell Restoration in the Gut Mucosa of Virologically Suppressed HIV-Infected Subjects After Isotretinoin Treatment: A Sub study of A5325. (Funded under the NIH-NIAID CTU) January 2015-Current
  • ACTG 5320: Viral Hepatitis C Infection Long-term Cohort Study (V-HICS) (Funded under the NIH-NIAID CTU) May 2014-December 2014
  • ACTG 5314: Effect of Reducing Inflammation with Low Dose Methotrexate on Inflammatory Markers and Endothelial Function in Treated and Suppressed HIV Infection. (Funded under the NIH-NIAID CTU) July 2014-Present
• HIV Counseling, Testing, and Referral Services, New Jersey Department of Health, Division of HIV, STD and TB Services. ($473,131 annual budget) September 1, 2014-Current
• HIV/AIDS Counseling and Testing/Notification Assistance Program, New Jersey Department of Health ($300,000 annual funding) July 1, 2016-Current
• HIV Prevention with Positives and Partner Services, New Jersey Department of Health and Senior Services ($150,000 annual funding). January –December 2017
• Ryan White Part C, Health Resources and Services Administration, (H76HA28079), “Early Intervention Services with Respect to HIV Disease,” ($1,157,397), January-December 2017
• Ryan White Part A and F, City of Newark, Department of Health & Human Services ($1,780,574), March 2017-present
• HIV Pre-Exposure Prophylaxis Demonstration Project to Prevent HIV in women. Gilead Sciences ($129,256.00) July 2016- Current
• HIV Care and Treatment Award, New Jersey Department of Health ($833,000 annual funding) July 1, 2016-Current
• The Division of HIV, STD and TB Services (DHSTS) STD Services/DIS Services ($101,787 annual funding) July 1, 2019-Current
• HPTN 069: A Phase II Randomized, Double-Blind, Study of the Safety and Tolerability of Maraviroc (MVC), Maraviroc + Emtricitabine (MVC+FTC), Maraviroc + Tenofovir disoproxil fumarate (MVC+TDF), or Tenofovir disoproxil fumarate + Emtricitabine (TDF+FTC) for Pre-Exposure Prophylaxis (PrEP) to Prevent HIV Transmission in At-Risk Men Who Have Sex with Men and in At-Risk Women ($11, 037) March 2015-May 2016
• An Open-Label Phase 3 Study of Telaprevir in Combination with Peginterferon Alfa-2a (Pegasys^®), and Ribavirin (Copegus^®) in Subjects Coinfected With Genotype 1 Hepatitis C Virus and Human Immunodeficiency Virus Type 1 (HCV/HIV), ($20,000) 2013-2014
• A Randomized, Double-Blind Phase 3B Study to Evaluate Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir vs ritonavir-boosted Atazanavir+Emtricitabine/Tenofovir in HIV-1 infected Antiretroviral Treatment-Naïve Women. GS-US-236-0128 Gilead Sciences ($24,588.50 Received to date), 2012-present
• A Multicenter, Double Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK0518 versus KALETRA in HIV-Infected Patients Switched From a Stable KALETRA-Based Regimen. Merck Pharmaceuticals ($15,000). January 2008-December 2010)
• Early Access of Raltegravir in combination with other antiretrovirals (ARVs) in highly treatment experienced HIV-1 infected subjects with limited to no treatment options. ($5,000) Merck Pharmaceuticals. January-June 2009
• Multicenter, Double-Blind, Randomized, Dose-Ranging, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics, and Antiretroviral Activity of L-000900612 in Combination with an Optimized Background Therapy (OBT), versus Optimized Background Therapy Alone, in HIV-Infected Patients with Documented Resistance to at least 1 Drug in each of the 3 Classes of Licensed Oral Antiretroviral Therapies, Merck Pharmaceuticals ($50,000) 2006-2008
• Influence of Hepatitis C virus coinfection on the outcome of HAART in HIV infected patients, Foundation of the University of Medicine and Dentistry of New Jersey (15,000 funding) 2005­2013, 2005-2014

Participating Investigator (Federally sponsored programs)

• 2UM1AI069419 Weill Cornell Medical college-New Jersey Medical School AIDS Clinical Trial Unit; NIH-NIAID ($1,099,189), 2013-2014
• Centers for Innovative Research to Control AIDS (HIV Prevention) National Institutes of Health. ($550,359 annual funding /$4,287,748 project costs) 2009-2012.
• Ryan White Part A, City of Newark, Department of Health & Human Services ($996,150), 2012­-2014
• Ryan White Part F, City of Newark, Department of Health & Human Services, Minority AIDS Initiative, ($400,000) 2012-2014
• Ryan White Part A, City of Newark, Department of Health & Human Services, ($1,070,968 project costs), 2011-2012
• Ryan White Part A, City of Newark, Department of Health & Human Services, ($1,162,864 project costs), 2010-2012
• Ryan White Part A, City of Newark, Department of Health & Human Services, ($746,524 project costs), 2009-2010
• Ryan White Part F, City of Newark, Department of Health & Human Services, Minority AIDS Initiative, ($403,926 project costs), 2011-2012
• Ryan White Part F, City of Newark, Department of Health & Human Services, Minority AIDS Initiative, ($350,000 project costs), 2010-2011
• Ryan White Part F, City of Newark, Department of Health & Human Services, Minority AIDS Initiative, ($100,000 project costs), 2009-2010
• Ryan White Part F, City of Newark, Department of Health & Human Services, Minority AIDS Initiative, ($103,955 project costs), 2008-2009
• Ryan White Part C, Health Resources and Services Administration, P06HA10803, HIV Capacity Development and Planning Grants, ($85,000 project costs), 2008-2011
• Ryan White Part A, City of Newark, Department of Health & Human Services, ($890,167 project costs), 2008-2009
• Terri Beirn CPCRA Clinical Trials Unit (AIDS Clinical Trials Group site), National Institutes of Health. ($623,452 annual budget- $2,655,964 project costs), 2007-2013. Funded Following Projects:
• ACTG 5241: The Optimized Treatment that Includes or Omits NRTIs
• (OPTIONS) Trial: A Randomized Strategy Study for HIV-1-Infected Treatment-Experienced Subjects Using the cPSS to select an Effective Regimen. NIH, NIAID. 2009-2013
• ACTG 5240: A Phase II Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Females. NIH, NIAID (2010-2012)
• ACTG 5221: A Strategy Study of Immediate Versus Deferred Initiation of Antiretroviral Therapy for HIV-Infected Persons Treated for Tuberculosis with CD4 < 200 cells/mm³. NIH, NIAID (201-2012)
• A5279: Phase III Clinical Trial of Ultra-Short-Course Rifapentine/Isoniazid for the Prevention of Active Tuberculosis in HIV-Infected Individuals with Latent Tuberculosis Infection. (Funded under the NIH-NIAID CTU) 2012-present
• ACTG 5269: The Activity of Nitazoxanide in Addition to Peginterferon Alfa-2a and Ribavirin in Chronic Hepatitis C Treatment-Naive Genotype 1 Subjects with HIV Co-Infection. NIH, NIAID, January 2011-December 2013. Site PI
• ACTG 5247: Evaluate the Immunogenicity of ZOSTAVAX (Zoster Vaccine Live) in HIV-infected patients, NIH, NIAID, 2010-2012. Site PI
• ACTG 5239: Pioglitazone Prior to HCV in NonResponders to Peg/IFN & RBV w/ Insulin Resistance, NIH, NIAID, 2010-2012. Site PI
• Ryan White Part A, City of Newark, Department of Health & Human Services, ($769,591 project costs), 2007-2008
• Ryan White Part A, City of Newark, Department of Health & Human Services, ($672,747 project costs), 2006-2007
• Ryan White Part A, City of Newark, Department of Health & Human Services, ($587,090 project costs), 2005-2006

 

B. Co-Investigator

• COVID-19 Registry: Evaluation of outcomes for all patients evaluated for COVID-19 at University Hospital. May 2020-Current
• Rutgers Corona Cohort (RCC): Cohort study of SARS-CoV-2 incidence, transmission, and disease severity in healthcare workers. (Funded by Rutgers CTSA). April 2020-Current
•  Asymptomatic Corona Trial (ACT) Treatment of asymptomatic healthcare worker study. (Funded by Rutgers CTSA). May 2020-Current
• RUXCOVID Novartis COVID19 Study. Phase 3 Randomized, Double blind, Placebo-Controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients with COVID-19 Associated Cytokine Storm. (Funded by Novartis). May 2020-Current.
• Remdesivir (GS-5734) for a patient with COVID-19 April 2020-Current
• Participant satisfaction with HIV prevention research. March 2020-Current
• Initiating PrEP in primary care July 2019-Current
• A5357: Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) for Viral Suppression in Adults Living With HIV-1(Funded under the NIH-NIAID CTU) March 2020-Current
• A5395: HCQ and Azithro for Non-hospitalized Persons with COVID-19 (HAz COVID Trial) (Funded under the NIH-NIAID CTU) May 2020-Current
• A5379: BEe-HIVe: B-Enhancement of HBV Vaccination in Persons Living With HIV (BEe-HIVe): Evaluation of HEPLISAV-B (BEe-HIVe) (Funded under the NIH-NIAID CTU) May 2020-Current
• A5366: Effects of SERM and HDACi on HIV-1 (Funded under the NIH-NIAID CTU) November 2018-Current
• A5375: Pharmacokinetic Study to evaluate double-dose levonorestrel emergency contraception in combination with efavirenz-based antiretroviral therapy or rifampicin-containing anti-tuberculosis therapy. (Funded under the NIH-NIAID CTU) November 2019-Current
• A5377 Safety, tolerability, pharmacokinetics, and antiviral activity of SAR441236, a tri-specific neutralizing antibody against HIV. (Funded under the NIH-NIAID CTU) November 2019-Current
• A5359: The LATITUDE Study Long-Acting (LA) Injectable Antiretroviral Therapy (ART) to standard of care (SOC) oral ART in previously non-adherent individuals. (Funded under the NIH-NIAID CTU) June 2019-Current
• A5360: The MINMON Study. A Single-arm Study to Evaluate the Feasibility and Efficacy of a Minimal Monitoring Strategy to Deliver Pan-genotypic Ribavirin-free HCV Therapy to Chronically Infected HCV Treatment Naïve Populations Globally: The MINMON Study (Funded under the NIH-NIAID CTU) November 2018-Current
• Ally Quest Piloting a Sequential Multiple-Assignment Randomization Trial to evaluate Ally Quest: a mHealth intervention for HIV-positive young MSM and TWSM to optimize HIV medication adherence and care outcomes (Funded by National Institutes of Health (NIH)). June 2020
• ACTG 5316: Evaluating Pharmacokinetic Interactions with Vaginal Ring Contraceptives and Antiretroviral Therapy (Funded under the NIH-NIAID CTU) January 2015-Present
•  TMC435-TiDP16-C212 A Phase III Open-Label Study to Evaluate the safety, tolerability and efficacy of TMC435 plus PegIFNa-2a (Pegasys) and ribavirin (Copegus) triple therapy in chronic hepatitis C genotype-1 infected subjects who are co-infected with human immunodeficiency virus type 1 (HIV-1), Tibotec Pharmaceuticals ($18,121 Received to date) 2011-2014
• ING112574 A Phase III study to demonstrate the antiviral activity and safety of dolutegravir in HIV-1-infected adult subjects with treatment failure on an integrase inhibitor-containing regimen. GlaxoSmithKline LLC- VIKING ($2,376 Received to date), 2011-present
• TMC125-C206: A Phase III randomized, double-blinded, placebo-controlled trial to investigate the efficacy, tolerability and safety of TMC125 as part of a TMC114/RTV and an investigator-selected OBR in HIV-1 infected subjects with limited to no treatment options. Tibotech Pharmaceuticals. ($15,000), 2011-2013
• A Phase III, randomized, double-blind trial of TMC278 25 mg q.d. versus efavirenz 600 mg q.d. in combination with a fixed background regimen consisting of tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naïve HIV-1 infected subject. Tibotech Pharmaceuticals. ($12,000). 2011-2013
• ING 112574 A Phase III Study to demonstrate the antiviral activity and safety of dolutegravir in HIV-1-infected adults subjects with treatment failure on an integrase inhibitor containing regimen (CCC/LINCC), GlaxoSmithKline LLC- VIKING ($2,570 Received to date), 2010-2012
• TMC 278-TiDP6-C209 A Phase III, randomized, double-blind trial of TMC278 25 mg q.d. versus efavirenz 600 mg q.d. in combination with a fixed background regimen consisting of tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naïve HIV-1 infected subjects. Tibotec Pharmaceuticals ($21,502 received to date), 2010-2012
• An open-label, multicenter trial to compare the efficacy, safety, and tolerability of PREZISTA/r by Gender and Race, when administered in combination with an individually optimized background regimen over a 48 week treatment period (GRACE). Tibotech Pharmaceuticals. ($18,000) 2009-2012
• Ryan White Part C, Health Resources and Services Administration, HIV Capacity Development and Planning Grants, ($100,000 project costs), 2009-2011
• TMC114-C-226: Early Access of TMC114 in combination with low dose ritonavir (RTV) and other antiretrovirals (ARVs) in highly treatment experienced HIV-1 infected subjects with limited to no treatment options. Tibotech Pharmaceuticals ($32,000). 2008-2011
• A Phase IV, Open-label, Randomized, Multicenter Study Evaluating Efficacy and Tolerability of Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir DF Compared to Unmodified HAART in HIV-1 Infected Subjects Who Have Achieved Virological Suppression on their HAART Regimen. Bristol Myers Squibb Pharmaceuticals ($9,000), 2006-2008
• Role of Glutathione in Immunity against tuberculosis. Sponsored by UMDNJ Foundation, $50,000, 2005-2006
• The GlaxoSmithKline ALOHA Study: A Phase IIIB, Randomized, Open-Label, Multicenter, Parallel-Arm Study to Evaluate the Short-Term Safety and Tolerability of the Abacavir/Lamivudine Fixed-Dose Combination Tablet Administered Once-Daily or the Separate Abacavir and Lamivudine Tablets Administered Twice-Daily, as Part of a Three or Four Drug Regimen, in Antiretroviral-Naïve HIV-1 Infected Subjects. (ESS10182), Glaxo Smith Kline. ($24,596) February 2004-December 2006

1. Swaminathan S, Minamoto GY; Rat-Bite fever. In: Rakel RE, Bope ET (eds): Conn’s Current Therapy, 2004, Chapter 35.
2. Hodder S, Chew D, Swaminathan S. Principles Of Gender-Specific Medicine. In: Adult Immunization in Women and Men, Principles of Gender-Specific Medicine. Lugato MJ Second Edition, Chapter-48; 563-582. Elsevier, New York City, 2010
3. Swaminathan S. Reflecting on HIV: A shift from desperation and fear to optimism and hope. Infectious Diseases Consultant. April 2020

1. Swaminathan S, Klein r, Howard AA, Lo Y, Gourevich, M, Schoenbaum E. Tow Step Tuberculin Skin Testing in Drug Users, 42^nd Annual Infectious Diseases Society of America Meeting, Abstract #403
2. Swaminathan S, Hom D, Negron B, Jones EL, Hodder SL, Prevalence of Hepatitis B in an inner-city HIV clinic. 43^rd Annual Infectious Diseases Society of America Meeting, San Francisco, 2005. Abstract # 835
3. Reilly, Swaminathan S, Reilly N, Hom DL, Jones-Lopez L, Hodder SL, Sexually Transmitted Diseases in an Urban Population of HIV Infected Women. 43^rd Annual Infectious Diseases Society of America Meeting, San Francisco, 2005; Abstract # 855
4. Swaminathan S, Chew D, Hodder SL. Impaired CD4 Response despite Effective HAART in Patients with Human Immunodeficiency (HIV) Coinfected with Hepatitis C (HCV). 44^th Annual Infectious Diseases Society of America Meeting, Toronto, 2006 (Oral Presentation)
5. Deka B, Swaminathan S, Hodder SL, Renal Dysfunction in HIV and Hepatitis C Co-infected patients on Antiretroviral therapy. 44^th Annual Infectious Diseases Society of America Meeting, Toronto, 2006. Abstract # 892
6. Chew D, Swaminathan S, Hodder SL. Medical Appointment Adherence and Virologic and Immunologic Outcomes in Antiretroviral Treatment (ART)-Naïve Patients with Human Immunodeficiency Virus (HIV) in an Urban HIV Clinic. 44^th Annual Infectious Diseases Society of America Meeting, 2006. Abstract # 939
7. Peyton, A. Samanta; S. Swaminathan. Acute Hepatitis Associated Aplastic Anemia. Digestive Diseases Week, Washington DC, 2007. Abstract # T1940c
8. Kudipudi R., Seiden J, Chew D., Swaminathan S., Li J., Kim S., Fennelly K, Hodder SL. Obstructive Lung Disease in an Urban Cohort of Human Immunodeficiency Virus (HIV)-1 Infected Persons. International AIDS Society, Sydney, 2007. Abstract # TUPEB097
9. Swaminathan S, Chew D, Fleming P, Li J, Hodder SL. Older Age as a Predictor of Virologic Suppression in Antiretroviral Therapy Naïve HIV-Infected Individuals Initiated on Antiretroviral Therapy. XVII International AIDS Conference, Sydney, Australia. July 2007. Abstract # WEPEB105
10. Makinde H, Swaminathan S, Brimacombe M, Roche N, Kuye O, and Hodder SL. Prevalence of Abnormal Anal Pap Smears in a Population of HIV Infected Women. 47th Annual Infectious Diseases Society of America Meeting. Philadelphia. October 2009. Abstract # 361
11. Haim S, Deshields R, Hodder Sl, Dave P, Swaminathan S. Improved Outcomes Among HIV-Infected Patients in an Urban Populations using effective Medical Case Management . Ryan White Grantee Meeting 2012, Washington DC, 2010
12. Goodwin-Fernandez A, Swaminathan S, Fernandes H, Hodder SL. The Prevalence of Antiretroviral Drug Resistance Mutations in antiretroviral Naïve HIV-1 Infected persons in Newark, New Jersey. 49^th annual IDSA. October 20-23, 2011. Boston, MA. USA. Abstract # 415
13. Shin-Pung Jen, Swaminathan S, Kapila R, Horng H. Clinical Experience with Aerosolized Antimicrobial Therapy in an Academic Tertiary Care Hospital. 49th Annual Infectious Diseases Society of America Meeting. Boston. October 20-23, 2011. Abstract # 292
14. Welt E, Mosquera R, Deshields R, Hodder SL, Swaminathan S. Improved Outcomes Among New Male HIV-Infected Patients in an Urban Population Using Effective Medical Case Management. Ryan White Grantee Meeting, Washington DC, 2012.
15. Swaminathan S, Deshields R, Rios E, Torres C, Abass K, Hodder SL. Reported Behavior Change and Attitudes on Prevention Studies Among Newark, NJ HIV Prevention Trials Network (HPTN) 064 Participants: Results of Exit Interview. XIX International AIDS Society. July 22-27, 2012. Washington DC. Abstract TUPE286
16. Banga J, Deshields R, Corasmin E, Swaminathan S, Chew D, Hodder SL, Care Coordination Services improve patient outcomes among HIV-Infected Urban Women. Ryan White Grantee Meeting, Washington DC, 2012.
17. Capunitan JC, Banga J, Swaminathan S, Hodder SL, Prevalence of Plasma Cell Dyscrasias in an Urban Population of HIV-I infected Persons. 50^th annual IDSA. October 2-6, 2012. San Francisco, CA. USA. Abstract# 287
18. Shin-Pung J, Horng H, Swaminathan S, Cennimo D, and Kapila K. Antimicrobial Restriction and Preauthorization: Easier Said Than Done? 53^rd annual IDSA. October 7-11, 2015. San Diego, CA. USA. Abstract# 51107
19. Derose J, Zucker J, Cennimo D, Swaminathan S. Rutgers – New Jersey Medical School HIV Screening Compliance – Are We Missing Opportunities? 53^rd annual IDSA. October 7-11, 2015. San Diego, CA. USA. Abstract# 52896
20. Nizami S, Zucker J, Swaminathan S. FIB-4: An Inexpensive Marker of Hepatocellular Carcinoma in Patients with HIV and Hepatitis C Co-infection. 53^rd annual IDSA. October 7-11, 2015. San Diego, CA. USA. Abstract# 52332
21. Koper C, Dharan N, Singh B, Chew D, Swaminathan S, Hodder S. Attitudes among Men and Women Regarding Pre-Exposure Prophylaxis to Prevent HIV Acquisition in an Urban HIV-Prevalent Setting in the United States. 53^rd annual IDSA. October 7-11, 2015. San Diego, CA. USA. Abstract# 52515
22. Zucker J, Sugalski G, Swaminathan S, Cennimo D. Differences in HIV Screening by age, gender, time of day and diagnosis in a high prevalence Emergency Department. 53^rd annual IDSA. October 7-11, 2015. San Diego, CA. USA. Abstract# 51013
23. Tlamsa A, Zucker J, Cennimo D, Sugalski G and Swaminathan S. An Evaluation of HIV Screening After Implementation of an EMR Reminder. 54^th Annual IDSA. New Orleans 26-30, 2016. LA, USA. Poster #415
24. Haywood AM, DeShields R, Chew D, DallaPiazza M, and Swaminathan S. Incentivized Care Coordination Services Improve Cervical Cancer Screening Rates Among HIV-infected Urban Women. Presented at the Ryan White All grantee Meeting Washington DC August 23-26, 2016.
25. Amico KR; Ramirez C; Caplan MR; Montgomery B; Stewart J; Hodder S; Swaminathan S; Darden-Tabb N; Young A; McCauley MB; Mayer K; Wilkin T; Landovitz RJ; Gulick R. US Women in the HPTN 069/ACTG 5305 Phase II Maraviroc PrEP study: A sub study evaluating acceptability and experiences. Presented at HIVR4P October 17-19, 2016
26. Banga J, Nizami S, Slim J, Nagarakanti S and Swaminathan S. Hepatitis C Virus Treatment Response to Ledipasvir/Sofosbuvir among patients co-infected with HIV and HCV: Real World Data in a Black Population. Accepter for poster presentation at 67the American Association for the Study of Liver Diseases, Boston, MA, USA. November 11-15, 2016.
27. Bekker LG, Li SS, Tolley B, Marzinke MA, Mgodi N, Justman JE, Swaminathan S, Adeyeye A, Farrior JH, Sista N. HPTN 076: TMC 278 LA safe, tolerable and acceptable for HIV pre-exposure prophylaxis. LB CROI 2017 Seattle 2017. Poster # 2429
28. Sista ND, Li S, Marzinke M, Mgodi N, Justman J, Swaminathan S, Adeyeye, A PiwowarManning E, Pathak S, Farrior J and Bekker L-G. HPTN 076: Safety and Pharmacokinetics of Rilpivirine LA in HIV.  Accepted for Poster Presentation at IAS, Paris, July21-23, 2017.
29. Maldonado S, Suglaski G, Closeil G, Swaminathan S. Implementing Routine HIV Testing in the Emergency Department Using Electronic Health Record Modifications at University Hospital, Newark, NJ. Accepted for Poster Presentation at IAS, Paris, July21-23, 2017.
30. Maldonado S, Suglaski G, Closeil G, Swaminathan S. Impact of Patient Navigators in Linkage to Care for HIV-Positive Patients in an Urban Emergency Department in Newark, NJ . Accepted for Poster Presentation at ID Week San Diego, CA October 2017
31. Banga J, Nizami S, Slim J, Nagarakanti S and Swaminathan S. Treatment Response to Ledipasvir/Sofosbuvir among patients co-infected with HIV and HCV: Real World Data in a Black Population, Final Analysis. Accepted for Poster Presentation at ID Week San Diego, CA October 2017
32. Marconi V, DallaPiazza M, Gai S, Somboonwit C, Swaminathan S, Taylor O, Ortiz A, Gupta C, Zulkiewicz B, Karns S, Harshbarger C, Freeman A, Galindo C, Lewis M. Planning to conduct a pragmatic trial: pre-implementation cross-site learnings from Positive Health Check. Oral presentation at: American Public Health Association meeting, 2017. Abstract # 383108.
33. Chew D, Tejura N, Closeill G, Nyaku A, Swaminathan S. Challenges in PrEP Implementation in an Urban Infectious Disease Clinic with a High Background HIV Prevalence, Presented at the Centers for Disease Control and Prevention STD Conference August 2018.
34. Reynoso-Vasquez N, Kothari P, Haywood, A, Swaminathan S, Singh B, DallaPiazza M. Assessment of factors impacting cervical cancer screening rates among urban women living with HIV/AIDS. Presented at ID Week San Francisco October 2018.
35. Haywood, AM, Delfyette J, DeShields R, DallaPiazza M, Swaminathan S. Intensive Care Coordination By A Community Health Worker Improved HIV Viral Load Suppression In Young Men Who Have Sex With Men. Accepted for Ryan White Conference Washington DC August 2020.
36. Portilla M, Dalla Piazza M., DeShields R, Swaminathan S. Ongoing Nurse Care Coordination among Persons with HIV and Hepatitis C Infections. Accepted for Ryan White Conference Washington DC August 2020.
37. SA Olender, KK Perez, AS Go, B Balani, EG Price-Haywood, NS Shah, S Wang, TL Walunas, S Swaminathan, J Slim, B Chin, S De Wit, SM Ali, A Soriano Viladomiu, P Robinson, RL Gottlieb, TYO Tsang, I-H Lee H Hu, RH Haubrich, AP Chokkalingam, L Lin, L Zhong, BN Bekele, R Mera-Giler, C Phulpin, H Edgar, J Gallant, H Diaz-Cuervo, LE Smith, AO Osinusi, DM Brainard, JI Bernardino, for the GS-US-540-5773 and GS-US-540-5807 Investigators. Remdesivir for severe COVID-19 versus a cohort receiving standard of care. Accepted at poster presentation at the IAS COVID-19 congress July 2020.
38. HPTN083 interim results: Pre-exposure prophylaxis (PrEP) containing long-acting injectable cabotegravir (CAB-LA) is safe and highly effective for cisgender men and transgender women who have sex with men (MSM,TGW). Accepted as an oral Presentation for AIDS 2020.
39. McGee-Avila, J. K., Swaminathan, S., Haywood, A., Haiken, H., Cervical cancer screening in Women Living with HIV at an Urban Ryan White Clinic in Newark, NJ. Accepted for an interactive poster presentation during the poster session “Poster Session: Women’s Health”, at the virtual convening of the Annual Research Meeting
40. Correia L, Tseng C, Portilla M, Swaminathan S. Barriers to Hepatitis C Elimination in an Urban Clinic Offering Integrated HIV/HCV Treatment. Accepted for poster Presentation at ID Week October 2020.
41. Kodali S, Sudyn A, Paer J, Maldonado S, Nyaku A, MD, Swaminathan S. Linkage to Care for Newly Diagnosed HIV Patients in a High-Prevalence Emergency Department. Accepted for poster Presentation at ID Week October 2020
42. Sudyn A, Paer J, Kodali S, Maldonado S, Nyaku A, MD, Swaminathan S. Linkage-to-Care Outcomes in Previously HIV-Positive Patients from a High Prevalence Urban Hospital ED. Accepted for poster Presentation at ID Week October 2020

F. Media

1. Star Ledger article: “New Jersey women participate in trial looking at new ways to prevent HIV.” Published August 21, 2014
2. HIV PrEP for Women Article in Opzij (Online Magazine, In Press)
3. PrEp for Women Rally, St. Luke’s Medical Center, New York, NY October 14, 2014
4. Featured Expert, New England Journal of Medicine Group Open Forum: Hepatitis C Expert Case Discussion, June 2015
5. Rutgers New Jersey Medical School, Pulse Article “Leading the Way in HIV Prevention”, September 2016
6. Rutgers New Jersey Medical School, Pulse Article “NJMS Takes the Lead in HIV Prevention”, September 2018.
7. Rutgers Today: “Bringing Research and Community Together To End HIV” February 2020.
8. Rutgers Today: Rutgers New Jersey Medical School Part of Worldwide HIV Vaccine Trial. February 2020.
9. Interview on Radio “Live with Dino Flammio” FM 101.5 “HIV Vaccine Study at New Jersey Medical School”. March 4, 2020
10. Come Together: Virtual Stakeholder Series Hosted by “Research with a Heart”: COVID-19 Update, Friday May 15, 2020
11. Come Together: Virtual Stakeholder Series Hosted by “Research with a Heart”: COVID-19 Clinical Trials Update, Friday June 19, 2020

Infectious Diseases Board Review Resident Lecture: Englewood Hospital and Medical Center, December 2004.

Treatment of Lower Gastrointestinal Infections, Infectious Diseases Fellowship Didactic Lecture New Jersey Medical School, June 18, 2004

Treatment of Viral Hepatitis, Infectious Diseases Fellowship Didactic Lecture New Jersey Medical School, December 14, 2005

Infectious Diseases Case Presentation, Infectious Diseases Grand Rounds New Jersey Medical School, September 22, 2006

Treatment of HIV-HCV co-infection, Infectious Diseases Fellowship Didactic Lecture New Jersey Medical School, October 19, 2006

Review of Upper Gastrointestinal Infections, Infectious Diseases Fellowship Didactic Lecture New Jersey Medical School, October, 19, 2006

Treatment of Sexually Transmitted Infections, Internal Medicine Residency Program Resident Lecture New Jersey Medical School, December 6, 2006

Toxoplasmosis. Clinical Case Conference, Department of Medicine New Jersey Medical School, April 25, 2007

Infectious Disease Case Presentation. Infectious Diseases Grand Rounds New Jersey Medical School, May 31, 2007

Hepatitis B Virus Treatment: Confusing As Ever, Infectious Diseases Fellowship Didactic Lecture New Jersey Medical School, January 16, 2008

Treatment of viral Hepatitis, Infectious Diseases Fellowship Didactic Lecture New Jersey Medical School, February 1, 2008

Hepatitis B and HIV Co-Infection, Infectious Diseases Fellowship Didactic Lecture New Jersey Medical School, April 10, 2008 Hepatitis C and HIV Co-Infection, Infectious Diseases Fellowship Didactic Lecture New Jersey Medical School, May 6, 2008

Hepatitis C Virus Treatment. Womens’ Support Group, University Hospital Infectious Diseases Practice, July 16, 2008

Hepatitis C Virus Treatment. Hepatitis C Support Group, University Hospital Infectious Diseases Practice, August 7, 2008

Hepatitis C Virus Treatment. Infectious Diseases Fellowship Didactic Lecture New Jersey Medical School, August 22, 2008

Treatment of Sexually Transmitted Infections, Internal Medicine Residency Program Resident Lecture New Jersey Medical School, November 7, 2007

Treatment of Sexually Transmitted Infections, Internal Medicine Residency Program Resident Lecture New Jersey Medical School, November 12, 2008

HIV Case Presentation, Infectious Diseases Grand Rounds New Jersey Medical School, June 12, 2009

New Hepatitis C Virus Treatments. Hepatitis C Support Group, University Hospital Infectious Diseases Practice, September 17, 2009

Hepatitis C virus and HIV co-infection Treatment update, AIDS Education and Training Center, September 24, 2009

Clinical Manifestations of HIV, Overlook Hospital, Internal Medicine Grand Rounds October 5, 2009

Clinical Manifestations of HIV, Internal Medicine Grand Rounds East General Hospital, February 3, 2010

Treatment of HIV-Hepatitis C Virus co-infection. Grand Rounds, Department of Medicine, New Jersey Medical School, February 9, 2010.

Treatment of Sexually Transmitted Infections, Infectious Diseases Fellowship Didactic Lecture New Jersey Medical School, March 3, 2010

Initial Approach to the Treatment Naïve HIV-Positive Patient, AIDS Education and Training Center, April 14, 2010

When to Start HIV treatment, Infectious Diseases Grand Rounds, New Jersey Medical School, August 5, 2010

Treatment of Hepatitis B virus Infection, Infectious Diseases Fellowship Didactic Lecture New Jersey Medical School, November 12, 2010

Treatment of Sexually Transmitted Infections, Internal Medicine Residency Program Resident Lecture New Jersey Medical School, December 22, 2010

Treatment of Hepatitis B virus Infection, Infectious Diseases Fellowship Didactic Lecture New Jersey Medical School, January 13, 2011

Treatment of HIV-Hepatitis C Co-Infection, AIDS Education and Treatment Center, February 8, 2011

Treatment of Hepatitis C, Part 1, Infectious Diseases Fellowship Didactic Lecture New Jersey Medical School, September 22, 2011

START Study Results Discussion, Community Event for HIV/AIDS Awareness, Newark, NJ, October 12, 2011

Treatment of HIV, Internal Medicine Residency Program Resident Lecture New Jersey Medical School, December 5, 2011

Treatment of Hepatitis C, Part 2, Infectious Diseases Fellowship Didactic Lecture New Jersey Medical School, December 16, 2011

Hepatitis C Virus: Infectious Disease Specialists Expert Forum, Washington DC, February 24, 2012

HIV Treatment, AIDS Education and Training Center, March 22, 2012

HIV Update, East Orange Community Health Center, AIDS Education and Training Center April 25, 2012

HIV Grand Rounds, Saint Joseph Medical Center, Paterson, NJ. AIDS Education and Training Center May 9, 2012

HIV Treatment Update, Internal Medicine Board Review Course Staten Island University Hospital, May 24, 2012

Direct Acting Agents for Hepatitis C, Infectious Diseases Fellowship Didactic Lecture New Jersey Medical School, June 12, 2012

Hepatitis C Training, Princeton University, AIDS Education and Training Center April 2, 2013

HIV Treatment Update, Medicine Grand Rounds May 21, 2013, AIDS Education and Training Center East Orange general Medical Center

Treatment of HIV-Hepatitis C virus Co-infection, Infectious Diseases Fellowship Didactic Lecture September 25, 2013

Treatment of Opportunistic Infections, Internal Medicine Residency Program Resident Lecture New Jersey Medical School, October 11, 2013

HIV Treatment Update in 2013, Medicine Grand Rounds Mountainside Hospital, AIDS Education and Training Center December 11, 2013

Infections in Solid Organ Transplant Recipients, Infectious Diseases Fellowship Didactic Lecture New Jersey Medical School, January 17, 2014

Overview of Rheumatic Fever in Adults, Clinical Case Conference, Department of Medicine New Jersey Medical School, January 23, 2014

Hepatitis C Treatment in Patients with HIV-HCV Co-Infection, February 11, 2014, Webinar for AIDS Education and Training Center.

Gastrointestinal Manifestations of HIV Infection, Grand Rounds, Division of Gastroenterology and Liver Diseases New Jersey Medical School, February 26, 2014

Infectious Disease Board Review, Infectious Diseases Fellowship Didactic Lecture New Jersey Medical School, March 26, 2014

Infectious Disease Board Review, Infectious Diseases Fellowship Didactic Lecture New Jersey Medical School, April 16, 2014

Treatment of Hepatitis C virus Infection among Adolescents infected with HIV and Hepatitis C, Robert Wood Johnson Medical Center, AIDS Education and Training Center April 29, 2014

Treatment of Hepatitis C virus Infection among Persons infected with HIV and Hepatitis C. Saint Michaels Medical Center, AIDS Education and Training Center May 12, 2014

Infectious Disease Board Review, Infectious Diseases Fellowship Didactic Lecture New Jersey Medical School, May 16, 2014

PrEP for Women Rally in Mount Sinai, Expert Panel Speaker, Mount Sinai School of Medicine, October 14, 2014

Overview of HIV Pre-Exposure Prophylaxis Guidelines, Robert Wood Johnson Medical School, October 20, 2014.

HIV Pre-Exposure Prophylaxis: Infectious Diseases Grand Rounds, Rutgers, New Jersey Medical School. October 31, 2014

Infections in Solid Organ Transplant Recipients, Infectious Diseases Fellowship Didactic Lecture New Jersey Medical School, January 16, 2015

Treatment of Hepatitis C Virus Infections, Webinar Coordinated by AIDS Education and Training Center May 11, 2015

Infectious Disease Board Review 1, Infectious Diseases Fellowship Didactic Lecture New Jersey Medical School, May 22, 2015

Infectious Disease Board Review 2, Infectious Diseases Fellowship Didactic Lecture New Jersey Medical School, May 29, 2015

HIV Pre-Exposure Prophylaxis: An Ounce of Prevention, New Jersey HIV Clinical Update Conference, AIDS Education and Treatment Center, June 4, 2015

• HIV Pre-Exposure Prophylaxis, Gay Men’s HIV Awareness Day, September 16, 2015
• HIV-Hepatitis C Treatment in 2015, Coordinated by AIDS Education and Training Center December 8, 2015
• Raritan Bay Medical Center Medicine Grand Rounds. HIV-Hepatitis C Treatment in 2016, Coordinated by AIDS Education and Training Center April 5, 2016.
• HIV Treatment Update from CROI 2016, sponsored by Clinical Care Options, April 5, 2016
• Infectious Diseases Fellowship Didactic Lecture New Jersey Medical School, April 8, 2016, HCV Case Discussion.
• HIV-Hepatitis C Treatment in 2016, New Jersey HIV Clinical Update Conference, AIDS Education and Treatment Center, Edison, NJ.  June 7, 2016
• HIV-Hepatitis C Treatment in 2016, Northeast AIDS Education and Treatment Center Annual Faculty Update, New Paltz, NY June 8, 2016.
• Antiretroviral Therapy: When to Start, What to Start, Sponsored by Clinical Care Options, Washington DC, June 14, 2016.
• Antiretroviral Therapy: Emphasis on Hepatitis and Comorbidities, Sponsored by Clinical Care Options, New York, NY. July 27, 2016.
• HIV PrEP with a special Emphasis on Women. Sponsored by AIDS Education and Treatment Center, New Brunswick, NJ. August 9, 2016
• HIV Treatment Update sponsored by Clinical Care Options, October 26, 2016, New York, NY
• HIV Treatment Update, Coordinated by AIDS Education and Training Center, East Orange General Hospital, December 6, 2016
• HIV-HCV Treatment Options, Weill-Cornell Medicine, New York, NY, December 2, 2016
• HIV-HCV Treatment Update, Coordinated by AIDS Education and Training Center, Cherry Hill, December 7, 2016w
• Management of Antiretroviral Therapy in Women, Sponsored by Clinical Care Options, Washington DC. March 27, 2017
• HIV Treatment Update, New Jersey HIV Clinical Update Conference, AIDS Education and Treatment Center, Edison, NJ.  June 8, 2017
• Contemporary Management of HIV Infection, Sponsored by Clinical Care Options, St. Petersburg, FL. June 30, 2017
• Contemporary Management of HIV Infection in Women, Sponsored by Clinical Care Options, New York, NY, July 11, 2017
• New Data from CROI 2017. Sponsored by Clinical Care Options, Brooklyn, NY. October 5, 2017
• Updates from Fall Conferences 2017, Sponsored by Clinical Care Options, Hackensack, NJ. November 28, 2017
• HIV/HCV Symposium: Eliminating Hep C in People Living with HIV in NYC” in collaboration with Project SUCCEED at the NYCDOH, sponsored by AIDS Education and Treatment Centers.  January 26, 2018
• Evolving Approaches to ART Modification, Sponsored by Clinical Care Options Medicine Grand Rounds at Howard University, Washington DC. February 6, 2018
• Aging and HIV. Sponsored by Clinical Care Options Medicine Grand Rounds at Howard University, Washington DC. February 6, 2018. April 14, 2018
• HIV Treatment Case Discussions, New Jersey HIV Clinical Update Conference, AIDS Education and Treatment Center, Edison, NJ.  June 5, 2018
• Rutgers New Jersey Medical School Infectious Diseases Fellowship Didactic Lecture New Jersey Medical School, June 8, 2018, HCV Case Discussion.
• Rutgers New Jersey Medical School Infectious Diseases Fellowship Didactic Lecture New Jersey Medical School, January 30, 2020, Ryan White Program Update.
• COVID-19 Notes from New Jersey, Hosted by Women in Leadership Forum May 7, 2020.
• First-line and Switch Strategies Using Current ART Regimens and COVID-19 Update. Sponsored by Clinical Care Options Webinar. June 24, 2020